DeuterOncology
Pre-clinicalWe are developing a deuterated MET kinase inhibitor as a potential ‘best in class’ targeted therapy for MET driven disease
Founded
2020
Focus
Small Molecules
About
We are developing a deuterated MET kinase inhibitor as a potential ‘best in class’ targeted therapy for MET driven disease
Company Info
TypePrivate
Founded2020
LocationLeuven, Belgium
StagePre-clinical
Contact
SIMILAR COMPANIES
Miracor Medical
Pre-clinical · Zaventem
AML Clinical Services
Pre-clinical · Leuven
Anacura
Pre-clinical · Ghent
Aseptic Technologies
Pre-clinical · Gembloux
Aspect Analytics
Pre-clinical · Leuven
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile